RIN Institute

RIN Institute is a clinical-stage biotechnology company based in Tokyo, Japan, specializing in the development of next-generation cancer immunotherapies. The company's core technology is the Artificial Adjuvant Vector Cell (aAVC) platform, which was originally developed at the RIKEN research institute. This platform engineers cells to present specific cancer antigens while simultaneously activating Natural Killer T (NKT) cells to trigger a robust immune response involving both innate and adaptive immunity. Their lead program, R-100, targets WT1-expressing hematologic malignancies and is currently in clinical development for acute myeloid leukemia. By leveraging the versatility of the aAVC platform, RIN Institute aims to provide curative treatments for a wide range of liquid and solid tumors.